CJC-1295 is a synthetic 30-amino-acid analogue of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) — a chemical modification that allows the peptide to bind to serum albumin, extending its biological half-life from minutes to approximately 6-8 days. Ipamorelin is a pentapeptide growth hormone releasing peptide (GHRP) that activates the ghrelin receptor (GHS-R1a) to trigger GH secretion from the pituitary gland.
The two peptides work through complementary and distinct pathways: CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, providing sustained baseline stimulation of GH production, while Ipamorelin acts through the ghrelin receptor to trigger acute, pulsatile GH release. This dual-pathway activation produces a synergistic amplification of growth hormone secretion — typically 2-3x greater than either peptide alone — while maintaining physiological release patterns.
What distinguishes this combination from other GH-stimulating protocols is Ipamorelin's remarkable selectivity. Unlike older GHRPs such as GHRP-6 or hexarelin, ipamorelin does not significantly increase cortisol, prolactin, or aldosterone levels, making it one of the cleanest growth hormone secretagogues available. This selectivity was established in the original 1998 characterization study and has been confirmed repeatedly in subsequent research.
The combined 1.2mg/2mg injectable formulation delivers both peptides subcutaneously for direct systemic absorption. The injectable route ensures maximum bioavailability of both peptides simultaneously, allowing the synergistic mechanism to function as designed for optimal growth hormone optimization under medical supervision.
Clinician-supervised, delivered to your door.
